Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers devise new approach to improve current T-cell therapy methods

T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

23 Feb 2016

Newly developed intravital microscopy system proves safe for use in humans

A team of Roswell Park Cancer Institute researchers has developed and evaluated the first intravital microscopy system shown to be safe for use in humans. Writing in the journal Nature Communications, the scientists report that their proprietary technology enabled them, for the first time ever, to visualize tumor blood vessels in real time.

22 Feb 2016

Majority of LAHNC patients rely on lifestyle-altering cost-coping strategies to manage treatment

The majority of patients with locally advanced head and neck cancers (LAHNC) rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients. DEK may help doctors understand how a person's immune system could be used to treat cancer or predict outcomes for patients.

18 Feb 2016

New drug combination shows promise for patients with non-small cell lung cancer

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment options is needed.

18 Feb 2016

New optogenetic technology could turn on immune cells to attack melanoma tumors

A new optogenetic technology developed at UMass Medical School, called optogenetic immunomodulation, is capable of turning on immune cells to attack melanoma tumors in mice. Using near-infrared light, UMMS researchers have shown they can selectively activate an immune response by controlling the flow of calcium ions into the cell. This breakthrough could lead to less invasive, and more controlled and selective, immunotherapies for cancer treatment.

17 Feb 2016

Wistar researchers find potential way for using STAT3 inhibitors to stop cancer progression

Imagine developing a drug designed to inhibit a protein that helps cancer cells proliferate and survive only to find that the drug does not perform very well in the clinic. This was the dilemma faced by scientists researching inhibitors of signal transducer and activator of transcription (STAT3), a protein that controls transcription by the STAT3 gene.

17 Feb 2016

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

Asterias Biotherapeutics, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc.

17 Feb 2016

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) is hosting its second Annual New Treatments in Oncology (ANTO) conference, focused on advances in cancer research, new treatments and patient care.

17 Feb 2016

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

The quest to bring immunotherapy into widespread clinical use against cancer and infectious diseases has made great strides in recent years.

15 Feb 2016

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB Investment, and Epidarex Capital.

12 Feb 2016

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO, TxCell and other senior management will either attend, present to, and meet investors at a number of leading forthcoming investor conferences.

10 Feb 2016

Study provides new insights into breast cancer metastasis

It has long been thought that cancer metastasizes, or spreads, when a single cancer cell escapes from the original tumor, travels through the bloodstream and sets up shop in distant organs. However, a growing body of evidence suggests that these bad actors don't travel alone; instead they migrate through the body in cellular clusters, like gangs.

2 Feb 2016

Immunotherapy News and Research

Latest Immunotherapy News and Research

Researchers devise new approach to improve current T-cell therapy methods

Newly developed intravital microscopy system proves safe for use in humans

Majority of LAHNC patients rely on lifestyle-altering cost-coping strategies to manage treatment

Researchers examine molecular profile of HPV-positive oropharyngeal squamous cell carcinoma

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

Uninsured and Medicaid patients have higher overall and cancer-specific mortality rates

Chemoradiation improves survival rates among subset of elderly head and neck cancer patients

DEK gene present in plasma can help predict outcomes for patients with head and neck cancer

New drug combination shows promise for patients with non-small cell lung cancer

New optogenetic technology could turn on immune cells to attack melanoma tumors

Wistar researchers find potential way for using STAT3 inhibitors to stop cancer progression

Asterias Biotherapeutics simplifies capital structure through previously announced Asset Swap with BioTime

CTCA hosts second ‘Annual New Treatments in Oncology’ conference

TUM researchers make progress in bringing immunotherapy to fight against cancer, infectious diseases

Apellis Pharmaceuticals completes $47.1M Series D preferred stock financing

TxCell to update on recent achievements in cellular therapy market at leading forthcoming investor conferences

Study provides new insights into breast cancer metastasis

Radiation could increase responses to innovative immune-based therapeutic approaches to fight cancer

Overall EU cancer, leukaemia mortality rates to fall in 2016

Clinicoradiological syndromes allow rapid recognition of EV71 neurological problems

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in